Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparison of gene expression between high- and low-Sost/sclerostin expressing osteocytes

ABSTRACT: Single-cell sorted cells from the osteocytic cell line Ocy454 were screened for high- and low-Sost/sclerostin expression to see changes in other gene expressions related to Sost/sclerostin.

ORGANISM(S): Mus musculus

PROVIDER: GSE102958 | GEO | 2018/08/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of Sclerostin Inactivation in a Mouse Model of Severe Dominant Osteogenesis Imperfecta

Project description:Osteogenesis imperfecta (OI) is a rare bone disease that is associated with fractures and low bone mass. Sclerostin inhibition is being evaluated as a potential approach to increase bone mass in OI. We had previously found that in Col1a1Jrt/+ mice, a model of severe OI, treatment with an anti-sclerostin antibody had a minor effect on the skeletal phenotype. In the present study, we assessed the effect of genetic sclerostin inactivation in the Col1a1Jrt/+ mouse. We crossed Col1a1Jrt/+ mice with Sost knockout mice to generate Sost-deficient Col1a1Jrt/+ mice and assessed differences between Col1a1Jrt/+ mice with homozygous Sost deficiency and Col1a1Jrt/+ mice with heterozygous Sost deficiency. We found that Col1a1Jrt/+ mice with homozygous Sost deficiency had higher body mass, femur length, trabecular bone volume, cortical thickness and periosteal diameter as well as increased biomechanical parameters of bone strength. Differences between genotypes were larger at the age of 14 weeks than at 8 weeks of age. Transcriptome analysis of RNA extracted from the tibial diaphysis revealed only 5 differentially regulated genes. Thus, genetic inactivation of Sost increased bone mass and strength in the Col1a1Jrt/+ mouse. It appears from these observations that the degree of Sost suppression that is required for eliciting a beneficial response can vary with the genetic cause of OI.

2023-04-04 | GSE220601 | GEO

Increased Endothelial Sclerostin Caused by Elevated DSCAM Mediates Multiple Trisomy 21 (Down Syndrome) Phenotypes

Project description:Trisomy 21 (T21), a recurrent aneuploidy occurring in 1:800 births, predisposes to congenital heart disease (CHD) and multiple extra-cardiac phenotypes. Despite a definitive genetic etiology, the mechanisms by which T21 perturbs development and maintenance remains poorly understood. We compared the transcriptome of CHD tissues from 49 T21 and 226 euploid (eCHD) patients. We resolved cell lineages that mis-expressed T21 transcripts by cardiac single-nucleus RNA-sequencing and RNA in situ hybridization. Compared to eCHD, T21 had increased chr21 gene expression, 11-fold greater levels (p=1.2E-8) of SOST (chr17), encoding the Wnt-inhibitor sclerostin, and 1.4-fold higher levels (p=8.7E-8) of the SOST transcriptional activator ZNF467 (chr7). Cardiac endothelial cells co-expressed SOST and ZNF467. T21 endothelial cells had 6.9-fold higher SOST (p=2.7E-27) with downregulation of Wnt pathway genes. Within the chr21 CHD critical region, the expression of DSCAM was correlated with SOST (p=1.9E-5) and ZNF467 (p=2.9E-4). Deletion of DSCAM in T21 endothelial cells derived from human induced pluripotent stem cells resulted in decreased sclerostin secretion. As Wnt signaling is critical for atrioventricular canal formation, bone health, and pulmonary vascular homeostasis, we conclude that T21-mediated increased sclerostin levels inappropriately inhibits Wnt activities and promotes Down syndrome phenotypes. These findings imply therapeutic potential for anti-sclerostin antibodies in T21.

2024-05-09 | GSE253244 | GEO

Sost

Project description:Rattus norvegicus Sost, sclerostin [Source:RGD Symbol;Acc:69358], is expressed in 1 baseline experiment(s);

| ENSRNOG00000020805 | ExpressionAtlas

Sost

Project description:Rattus norvegicus Sost, sclerostin [Source:RGD Symbol;Acc:69358], is differentially expressed in 12 experiment(s);

| ENSRNOG00000020805 | ExpressionAtlas

SOST

Project description:Monodelphis domestica SOST, sclerostin [Source:NCBI gene;Acc:100009840], is expressed in 1 baseline experiment(s);

| ENSMODG00000037336 | ExpressionAtlas

Ablation of the Sost gene prevents hallmarks of calcific aortic valve disease in a high-cholesterol mouse model

Project description:The purpose of this study was to understand the effect of sclerostin genetic ablation (gene: Sost) on aortic valve fibrocalcification in an aged, high-cholesterol diet mouse model. Sclerostin is a potent agent in bone remodeling. It both blocks Wnt-mediated osteoblast bone deposition and spurs RANKL-mediated osteoclast maturation and subsequent bone resorption. A monoclonal antibody was recently approved as a treatment for post-menopausal osteoporosis but clinical trials indicated potential cardiovascular side effects. This study aimed to begin to understand the potential role of sclerostin in the aortic valve.

2024-12-01 | GSE190295 | GEO

SOST

Project description:Sus scrofa SOST, sclerostin [Source:VGNC Symbol;Acc:VGNC:93345], is differentially expressed in 1 experiment(s);

| ENSSSCG00000039204 | ExpressionAtlas

SOST

Project description:Homo sapiens SOST, sclerostin [Source:HGNC Symbol;Acc:HGNC:13771], is differentially expressed in 57 experiment(s);

| ENSG00000167941 | ExpressionAtlas

SOST

Project description:Oryctolagus cuniculus SOST, sclerostin [Source:HGNC Symbol;Acc:HGNC:13771], is expressed in 1 baseline experiment(s);

| ENSOCUG00000002947 | ExpressionAtlas

SOST

Project description:Homo sapiens SOST, sclerostin [Source:HGNC Symbol;Acc:HGNC:13771], is expressed in 20 baseline experiment(s);